122 related articles for article (PubMed ID: 528082)
21. [Rosette formation phenomenon in the presence of tumor antigen].
Saraeva ZM; Tereshchenko IP
Vopr Onkol; 1979; 25(2):66-7. PubMed ID: 425410
[No Abstract] [Full Text] [Related]
22. Studies on the mechanism of the anti-melanoma effect of polyinosinic-polycytidylic acid (PIC). II. Decreased growth of B-16 melanoma from prior exposure to the tumor. Abrogation of this response by PIC.
Bart RS; Kopf AW; Lam S
J Invest Dermatol; 1972 Dec; 59(6):442-4. PubMed ID: 4643883
[No Abstract] [Full Text] [Related]
23. [Mitogenic activity of melanoma extracts in leucocyte cultures (author's transl)].
Lischka G
Arch Dermatol Res (1975); 1975 Sep; 253(2):105-12. PubMed ID: 1190833
[TBL] [Abstract][Full Text] [Related]
24. Intralesional BCG, intravenous immune lymphocytes, and immunization with neuraminidase-treated tumor cells to manage melanoma; A clinical assessment.
Seigler HF; Shingleton WW; Pickrell KL
Plast Reconstr Surg; 1975 Mar; 55(3):294-8. PubMed ID: 1118487
[TBL] [Abstract][Full Text] [Related]
25. Some aspects of the immune defense against cancer. II. In vitro studies on human tumors.
Hellström I; Hellström KE
Cancer; 1971 Nov; 28(5):1269-71. PubMed ID: 5125674
[No Abstract] [Full Text] [Related]
26. Lymphocyte cytotoxicity of patients developing multiple primary melanomas.
Mukherji B; Dayal Y
Cancer; 1980 Oct; 46(7):1566-71. PubMed ID: 6968241
[TBL] [Abstract][Full Text] [Related]
27. Tumor specific immunity to mouse melanoma in vitro.
Peter CR; Wilson BJ; Malley A; Eisenhut DA; Hu F
Proc Soc Exp Biol Med; 1979 Jan; 160(1):109-13. PubMed ID: 419115
[No Abstract] [Full Text] [Related]
28. Antiserum against tyrosinase from mouse melanoma.
Ohtaki N; Miyazaki K
J Invest Dermatol; 1972 Apr; 58(4):238-41. PubMed ID: 4623203
[No Abstract] [Full Text] [Related]
29. Evidence for tumor-specific immunity in human malignant melanoma.
Nagel GA; Piessens WF; Stilmant MM; Lejeune F
Eur J Cancer (1965); 1971 Feb; 7(1):41-7. PubMed ID: 5576728
[No Abstract] [Full Text] [Related]
30. Uveitis caused by cytotoxic immune response to cutaneous malignant melanoma in swine: destruction of uveal melanocytes during tumor regression.
Lentz KJ; Burns RP; Loeffler K; Feeney-Burns L; Berkelhammer J; Hook RR
Invest Ophthalmol Vis Sci; 1983 Aug; 24(8):1063-9. PubMed ID: 6874271
[TBL] [Abstract][Full Text] [Related]
31. Prolonged BCG treatment of melanoma: does it suppress the immune capacity?
Helander I; Nordman E; Häkkinen IP; Toivanen A
Br J Dermatol; 1979 Oct; 101(4):421-7. PubMed ID: 508607
[TBL] [Abstract][Full Text] [Related]
32. [Immunological conditions in patients with malignant melanoma of the skin].
Kristensen E
Ugeskr Laeger; 1976 Feb; 138(8):463-8. PubMed ID: 1258214
[No Abstract] [Full Text] [Related]
33. [Evaluation of T- and B-cell immunity of regional lymph nodes in patients with skin melanoma and prognosis of the disease].
Serov AA; Kadagidze ZG
Vopr Onkol; 1983; 29(12):18-20. PubMed ID: 6607569
[TBL] [Abstract][Full Text] [Related]
34. A rapid assay for stimulation of human lymphocytes by tumor-associated antigens.
Roth JA; Grimm EA; Morton DL
Cancer Res; 1976 Sep; 36(9 pt.1):3001-10. PubMed ID: 975069
[TBL] [Abstract][Full Text] [Related]
35. [Immunological reactions of skin melanoma patients to nonspecific and adaptive immunotherapy].
Trapeznikov NN; Iavorskiĭ VV; Kadagidze ZG; Malaev SG; Kupin VI
Vopr Onkol; 1977; 23(8):27-33. PubMed ID: 906404
[TBL] [Abstract][Full Text] [Related]
36. Lymphocyte mediated reactivity against malignant melanoma detected by a microcytotoxicity assay employing technetium-99m labeled target cells.
Gillespie GY; Barth RF
Cancer; 1978 Jun; 41(6):2174-82. PubMed ID: 350374
[No Abstract] [Full Text] [Related]
37. Immunobiology of human cutaneous melanoma.
Cochran AJ; Wen DR; Stene M; Fairhurst MV; Hoon DS
Prog Clin Biol Res; 1988; 256():597-618. PubMed ID: 3368501
[No Abstract] [Full Text] [Related]
38. Reactivity in neoplasia, preneoplasia, and pregnancy of lymphocytes against fetal extracts: cross-reactions between man and mouse.
Pasternak G; Schlott B; Reinhöfer J; Gryschek G; von Broen B; Albrecht S
J Natl Cancer Inst; 1982 Nov; 69(5):997-1004. PubMed ID: 6957663
[TBL] [Abstract][Full Text] [Related]
39. Delayed cutaneous sensitivity reactions to extracts of autologous malignant melanoma: a second look.
Bluming AZ; Vogel CL; Ziegler JL; Kiryabwire JW
J Natl Cancer Inst; 1972 Jan; 48(1):17-24. PubMed ID: 4652371
[No Abstract] [Full Text] [Related]
40. [Changes in certain immunological parameters in patients with malignant skin melanoma].
Lukács L; Bárdosi L; Somos Z; Kocsis B
Orv Hetil; 1985 Apr; 126(14):819-26. PubMed ID: 3873050
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
